HK Stock Market Move | SCIENTECH (02291) rose more than 18% in the morning. The MemoSorb ASD/VSD occluder has obtained a market license in Saudi Arabia.

SCIENTECH (02291) rose more than 18% in the morning, and as of the time of writing, it was up 16.49% at 13.07 Hong Kong dollars, with a trading volume of 50.0935 million Hong Kong dollars. On the news front, in July, SCIENTECH's independently developed MemoSorb biodegradable atrial septal defect (ASD) occluder and fully biodegradable ventricular septal defect (VSD) occluder received approval for sale in the medical device market in Saudi Arabia. As early as April, the biodegradable patent foramen ovale (PFO) occluder and transcatheter aortic valve replacement (TAVR) system had already obtained approval for sale in Saudi Arabia. It is reported that Saudi Arabia, as one of the largest medical markets in the Middle East, is known for its high standards and strict requirements for SFDA certification, which is widely recognized by the Gulf Cooperation Council (GCC) countries and surrounding markets. This approval signifies that SCIENTECH's structural heart disease solution system, centered around the MemoSorb PFO/ASD/VSD occluder matrix and ScienCrown TAVR system, has now been fully implemented in the Middle East market, obtaining recognition from overseas regulatory authorities and laying a solid foundation for future clinical applications in the Middle East and serving more cardiovascular disease patients globally.